Sabit, HusseinHusseinSabitArneth, BorrosBorrosArnethAltrawy, AfafAfafAltrawyGhazy, AyshaAyshaGhazyAbdelazeem, Rawan M.Rawan M.AbdelazeemAdel, AmroAmroAdelAbdel-Ghany, ShaimaaShaimaaAbdel-GhanyAlqosaibi, Amany I.Amany I.AlqosaibiDeloukas, PanosPanosDeloukasTaghiyev, Zulfugar T.Zulfugar T.Taghiyev2026-01-212026-01-212025https://jlupub.ub.uni-giessen.de/handle/jlupub/21251https://doi.org/10.22029/jlupub-20596The intersection of COVID-19 and cardiovascular disease (CVD) has emerged as a significant area of research, particularly in understanding the impact of antiplatelet therapies like ticagrelor and clopidogrel. COVID-19 has been associated with acute cardiovascular complications, including myocardial infarction, thrombosis, and heart failure, exacerbated by the virus’s ability to trigger widespread inflammation and endothelial dysfunction. MicroRNAs (miRNAs) play a critical role in regulating these processes by modulating the gene expressions involved in platelet function, inflammation, and vascular homeostasis. This study explores the potential of miRNAs such as miR-223 and miR-126 as biomarkers for predicting resistance or responsiveness to antiplatelet therapies in COVID-19 patients with cardiovascular disease. Identifying miRNA signatures linked to drug efficacy could optimize treatment strategies for patients at high risk of thrombotic events during COVID-19 infection. Moreover, understanding miRNA-mediated pathways offers new insights into how SARS-CoV-2 exacerbates CVD, particularly through mechanisms like cytokine storms and endothelial damage. The findings of this research could lead to personalized therapeutic approaches, improving patient outcomes and reducing mortality in COVID-19-associated cardiovascular events. With global implications, this study addresses the urgent need for effective management of CVD in the context of COVID-19, focusing on the integration of molecular biomarkers to enhance the precision of antiplatelet therapy.enNamensnennung 4.0 Internationalddc:610